SCHEMBL6489965

SCHEMBL6489965

CC(OC(=O)N1CCC2=C(C1)C(=O)N(Cc1ccccc1)CN2C)c1cc2ccccc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.38
HRH4 Q9H3N8 3/20 0.34
CCKBR P32239 1/20 0.34
CALCRL Q16602 1/20 0.32
DRD2 P14416 2/20 0.32
DRD3 P35462 2/20 0.32
HRH1 P35367 1/20 0.32
KDM4E B2RXH2 2/20 0.32
ALOX5 P09917 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
IDO1 P14902 1/20 0.31
AKR1C3 P42330 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PARP1 P09874 1/20 0.31
PTGDR2 Q9Y5Y4 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6486678 0.84 KDR (0.46) KDRHRH4CCKBRPTGDR2
SCHEMBL6487201 0.84 KDR (0.37) KDRHRH4CALCRLDRD2DRD3
SCHEMBL6487338 0.77 TMEM97 (0.47) HRH1ALDH1A1HPGDHSD17B10
SCHEMBL6485050 0.76 POLB (0.39) DRD3KDM4EALDH1A1TSHRL3MBTL1
SCHEMBL6501727 0.76 HTR2B (0.40) KDRDRD2
SCHEMBL6489803 0.76 CLPP (0.40) KDRALDH1A1LMNATP53
SCHEMBL6487433 0.76 KDR (0.43) KDRCALCRLHPGDIDO1PTGDR2
SCHEMBL6489961 0.74 TMEM97 (0.38) KDRPTGDR2
SCHEMBL6486752 0.74 TMEM97 (0.36) ALDH1A1LMNATP53
SCHEMBL6496189 0.74 HRH3 (0.39) ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6869958-B2 Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-03-22 US disclosed
US-20040038960-A1 Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors LI JIE JACK (US) 2004-02-26 US disclosed
WO-2004014909-A1 FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038960-A1 Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors MMP9, MMP3, MMP13 KDR 3681/4885HRH4 883/4885CCKBR 4411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.